Michelle Furtado

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Peter Hillmen, Alexandra Pitchford, Adrian Bloor et al. · The Lancet Oncology · 2023 · 106 citations · Full text

Medicine, Immunology, Pharmacotherapy +14

Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma

Michelle Furtado, Rod Johnson, Anton Kruger et al. · British Journal of Haematology · 2014 · 50 citations

Medicine, Oncology, Pharmacotherapy +16

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Peter Hillmen, Alexandra Pitchford, Adrian Bloor et al. · Blood · 2021 · 36 citations

Medicine, Pharmacology, Pharmacotherapy +5

Antimutagenic Potential of<i>Solanum lycocarpum</i>against Induction of Chromosomal Aberrations in V79 Cells and Micronuclei in Mice by Doxorubicin

Denise Crispim Tavares, Carla Carolina Munari, Marcelo Gonzaga de Freitas Araújo et al. · Planta Medica · 2011 · 21 citations · Full text

Pharmacy, Genetics, Toxicology +10

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin

Michelle Furtado, Simon Rule · Clinical Medicine Insights Oncology · 2012 · 18 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17